KR102491125B1 - Sumo 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물 - Google Patents

Sumo 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물 Download PDF

Info

Publication number
KR102491125B1
KR102491125B1 KR1020177002906A KR20177002906A KR102491125B1 KR 102491125 B1 KR102491125 B1 KR 102491125B1 KR 1020177002906 A KR1020177002906 A KR 1020177002906A KR 20177002906 A KR20177002906 A KR 20177002906A KR 102491125 B1 KR102491125 B1 KR 102491125B1
Authority
KR
South Korea
Prior art keywords
membered
hydrogen
optionally substituted
compound
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177002906A
Other languages
English (en)
Korean (ko)
Other versions
KR20170032334A (ko
Inventor
매튜 오. 더피
딜런 잉글랜드
스코트 프리즈
치겐 후
스티븐 피. 랭스턴
찰스 매킨타이어
히로타케 미즈타니
코지 오노
헤 수
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55019950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102491125(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20170032334A publication Critical patent/KR20170032334A/ko
Application granted granted Critical
Publication of KR102491125B1 publication Critical patent/KR102491125B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5352—Phosphoranes containing the structure P=C-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020177002906A 2014-07-01 2015-06-30 Sumo 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물 Active KR102491125B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462019756P 2014-07-01 2014-07-01
US62/019,756 2014-07-01
US201562185678P 2015-06-28 2015-06-28
US62/185,678 2015-06-28
PCT/US2015/038712 WO2016004136A1 (en) 2014-07-01 2015-06-30 Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Publications (2)

Publication Number Publication Date
KR20170032334A KR20170032334A (ko) 2017-03-22
KR102491125B1 true KR102491125B1 (ko) 2023-01-20

Family

ID=55019950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177002906A Active KR102491125B1 (ko) 2014-07-01 2015-06-30 Sumo 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물

Country Status (39)

Country Link
US (6) US9683003B2 (enExample)
EP (3) EP3901159A1 (enExample)
JP (4) JP6603712B2 (enExample)
KR (1) KR102491125B1 (enExample)
CN (1) CN106999479B (enExample)
AU (1) AU2015284135B2 (enExample)
BR (1) BR112016030787B1 (enExample)
CA (1) CA2953132C (enExample)
CL (1) CL2016003398A1 (enExample)
CR (1) CR20170021A (enExample)
CY (1) CY1122808T1 (enExample)
DK (1) DK3164130T3 (enExample)
DO (1) DOP2016000339A (enExample)
EA (1) EA034119B1 (enExample)
EC (1) ECSP17006751A (enExample)
ES (1) ES2754359T3 (enExample)
GE (2) GEP20197047B (enExample)
HR (1) HRP20191979T1 (enExample)
HU (1) HUE045748T2 (enExample)
IL (1) IL249820B (enExample)
LT (1) LT3164130T (enExample)
ME (1) ME03574B (enExample)
MX (1) MX376054B (enExample)
MY (1) MY183649A (enExample)
NZ (1) NZ728162A (enExample)
PE (1) PE20170520A1 (enExample)
PH (1) PH12016502595B1 (enExample)
PL (1) PL3164130T3 (enExample)
PT (1) PT3164130T (enExample)
RS (1) RS59474B1 (enExample)
SG (1) SG11201610476VA (enExample)
SI (1) SI3164130T1 (enExample)
SM (1) SMT201900600T1 (enExample)
TN (1) TN2016000581A1 (enExample)
TW (1) TWI680970B (enExample)
UA (1) UA122963C2 (enExample)
UY (1) UY36198A (enExample)
WO (1) WO2016004136A1 (enExample)
ZA (1) ZA201700386B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173413B1 (en) 2012-02-17 2019-05-01 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
EP3901159A1 (en) 2014-07-01 2021-10-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
US10465447B2 (en) 2015-03-12 2019-11-05 Baker Hughes, A Ge Company, Llc Cutting elements configured to mitigate diamond table failure, earth-boring tools including such cutting elements, and related methods
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
MX2019003843A (es) 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
CA3049739A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US10400517B2 (en) 2017-05-02 2019-09-03 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and related tools and methods
WO2019060536A1 (en) 2017-09-21 2019-03-28 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
BR112020010815A2 (pt) 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos
US20210015915A1 (en) 2018-03-23 2021-01-21 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
CN112312904B (zh) * 2018-04-16 2025-01-07 C4医药公司 螺环化合物
JP7352582B2 (ja) * 2018-07-09 2023-09-28 武田薬品工業株式会社 Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与
US10570668B2 (en) 2018-07-27 2020-02-25 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and mitigate polycrystalline, superabrasive material failure earth-boring tools including such cutting elements, and related methods
CN109354569A (zh) * 2018-11-27 2019-02-19 常州大学 一种1,3-二溴-4-氟苯的制备方法
WO2020176643A1 (en) * 2019-02-26 2020-09-03 Millennium Pharmaceuticals, Inc. Compounds useful as adjuvants
EP3930719B1 (en) * 2019-02-27 2025-08-20 Takeda Pharmaceutical Company Limited Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
CN112402608B (zh) * 2020-11-30 2021-09-07 深圳先进技术研究院 5-烷氧基吲哚-3-乙烯基喹啉盐作为靶向可迁移光敏剂的应用
WO2021203001A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme
US20230218618A1 (en) * 2020-05-15 2023-07-13 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies
US12134938B2 (en) 2021-02-05 2024-11-05 Baker Hughes Oilfield Operations Llc Cutting elements for earth-boring tools, methods of manufacturing earth-boring tools, and related earth-boring tools
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
US11920409B2 (en) 2022-07-05 2024-03-05 Baker Hughes Oilfield Operations Llc Cutting elements, earth-boring tools including the cutting elements, and methods of forming the earth-boring tools
JP2025534374A (ja) * 2022-09-30 2025-10-15 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｓｕｍｏ活性化酵素阻害剤としての化合物
WO2024099438A1 (zh) * 2022-11-11 2024-05-16 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
WO2024110863A1 (en) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited Process and intermediates for preparing ((1r,2s,4r)-4-((5-(4-((r)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate
CN117209449B (zh) * 2023-09-14 2025-11-28 上海毕得医药科技股份有限公司 一种2-(三氟甲基)噻唑类化合物的合成方法
NL2035852B1 (en) 2023-09-21 2025-03-28 Academisch Ziekenhuis Leiden Enhancement of t cell mediated therapies
CN119371416B (zh) * 2024-12-23 2025-05-30 上海达歌生物医药科技有限公司 一种通过氧杂环丁烷开环以构建4-取代异香豆素及其类似物的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123169A1 (en) 2012-02-17 2013-08-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
US20040023901A1 (en) 2002-02-28 2004-02-05 Cook Phillip D. Nucleoside 5'-monophosphate mimics and their prodrugs
JP2005525398A (ja) * 2002-04-10 2005-08-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
CA2493816A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2004022559A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
CN1701073B (zh) 2002-09-04 2011-06-22 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2004043955A1 (en) 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
JPWO2005051949A1 (ja) 2003-11-26 2007-06-21 住友製薬株式会社 新規縮合イミダゾール誘導体
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ユビキチンリガーゼ阻害剤
AU2006210422B2 (en) 2005-02-04 2012-09-13 Takeda Pharmaceutical Company Limited Inhibitors of E1 activating enzymes
WO2007044426A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
CN106008512B (zh) * 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
HRP20110017T1 (hr) * 2006-08-08 2011-02-28 Millennium Pharmaceuticals Spojevi heteroarila korisni kao inhibitori e1 aktivirajućih enzima
JP5539864B2 (ja) 2007-06-12 2014-07-02 アカオゲン，インコーポレーテッド 抗菌剤
KR101925902B1 (ko) 2007-08-02 2018-12-06 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ1 활성화 효소 억제제의 합성 방법
WO2009082691A1 (en) 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en) 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282571B2 (en) 2008-08-20 2014-12-11 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP3587434A1 (en) 2008-09-23 2020-01-01 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with click components for conjugation with ligands
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG10201402148SA (en) 2009-05-14 2014-07-30 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
CA2771190C (en) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
CA2806341C (en) 2010-07-29 2020-03-24 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
MX2014002015A (es) 2011-08-24 2014-03-27 Millennium Pharm Inc Inhibidores de la enzima activadora de nedd8.
WO2013066729A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
BR112015032902A8 (pt) * 2013-07-02 2019-12-24 Millennium Pharm Inc compostos de heteroarila, seus usos e composições farmacêuticas
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
RU2019131017A (ru) 2013-10-21 2019-11-25 Мерк Патент Гмбх Соединения гетероарила в качестве ингибиторов btk и их применение
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
EP3901159A1 (en) 2014-07-01 2021-10-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123169A1 (en) 2012-02-17 2013-08-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Also Published As

Publication number Publication date
MX2016016993A (es) 2017-02-27
TN2016000581A1 (en) 2018-04-04
IL249820B (en) 2019-09-26
SMT201900600T1 (it) 2020-01-14
DK3164130T3 (da) 2019-10-28
HUE045748T2 (hu) 2020-01-28
EP3164130A1 (en) 2017-05-10
TW201613903A (en) 2016-04-16
UY36198A (es) 2016-01-29
US20220331316A1 (en) 2022-10-20
BR112016030787A2 (pt) 2017-08-22
CY1122808T1 (el) 2021-05-05
IL249820A0 (en) 2017-02-28
CA2953132A1 (en) 2016-01-07
PE20170520A1 (es) 2017-05-24
GEAP201914395A (en) 2019-06-10
US10780090B2 (en) 2020-09-22
AU2015284135B2 (en) 2019-11-28
US20160009744A1 (en) 2016-01-14
PH12016502595A1 (en) 2017-04-24
WO2016004136A1 (en) 2016-01-07
UA122963C2 (uk) 2021-01-27
SG11201610476VA (en) 2017-01-27
JP2024012558A (ja) 2024-01-30
US9683003B2 (en) 2017-06-20
US20230293522A1 (en) 2023-09-21
GEP20197047B (en) 2019-12-10
BR112016030787B1 (pt) 2022-12-20
PH12016502595B1 (en) 2021-09-10
ME03574B (me) 2020-07-20
US20200085821A1 (en) 2020-03-19
NZ728162A (en) 2023-06-30
EP3517112B1 (en) 2021-04-07
ECSP17006751A (es) 2017-02-24
EP3517112A1 (en) 2019-07-31
JP2021178869A (ja) 2021-11-18
SI3164130T1 (sl) 2019-12-31
EP3164130B1 (en) 2019-08-07
US20170216290A1 (en) 2017-08-03
ZA201700386B (en) 2018-11-28
HRP20191979T1 (hr) 2020-02-07
US20170002032A9 (en) 2017-01-05
JP2017524734A (ja) 2017-08-31
BR112016030787A8 (pt) 2021-07-20
PT3164130T (pt) 2019-11-18
US20180311239A1 (en) 2018-11-01
RS59474B1 (sr) 2019-12-31
CL2016003398A1 (es) 2017-12-29
CA2953132C (en) 2023-04-11
PL3164130T3 (pl) 2020-02-28
EA201790108A1 (ru) 2017-07-31
JP2020023538A (ja) 2020-02-13
AU2015284135A1 (en) 2017-02-09
TWI680970B (zh) 2020-01-01
KR20170032334A (ko) 2017-03-22
EA034119B1 (ru) 2019-12-30
EP3901159A1 (en) 2021-10-27
US9962386B2 (en) 2018-05-08
JP6603712B2 (ja) 2019-11-06
MY183649A (en) 2021-03-05
DOP2016000339A (es) 2017-03-15
LT3164130T (lt) 2019-11-25
EP3164130A4 (en) 2018-02-14
CR20170021A (es) 2017-04-04
CN106999479A (zh) 2017-08-01
CN106999479B (zh) 2021-07-16
ES2754359T3 (es) 2020-04-17
MX376054B (es) 2025-03-07
US10335410B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
KR102491125B1 (ko) Sumo 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물
TWI894229B (zh) 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物
CA2916468C (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
TW201838966A (zh) 取代的二氫茚－４－甲醯胺及其類似物以及其使用方法
TW200819443A (en) An imidazole derivative
EA047452B1 (ru) Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead
HK1237266B (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
HK1237266A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000